Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 30, 24 | -0.03 Decreased by -65.52% | - |
| Mar 31, 24 | -0.02 Decreased by -131.49% | - |
| Dec 31, 23 | 0.02 Decreased by -64.17% | - |
| Sep 30, 23 | 0.03 Decreased by -32.79% | - |
| Jun 30, 23 | -0.02 Decreased by -24.29% | - |
| Mar 31, 23 | 0.08 | - |
| Dec 31, 22 | 0.05 | - |
| Sep 30, 22 | 0.05 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 - | -451.64 K - | Decreased by N/A% - |
| Jun 30, 23 | 0.00 - | -264.39 K - | Decreased by N/A% - |